ストックスクリーナーアプリを入手
15.55
7.39%
-1.24
前日終値:
$16.79
開ける：
$16.35
24時間の取引高:
2.13M
Relative Volume:
0.77
時価総額：
$2.34B
収益：
-
当期純損益:
$-647.68M
株価収益率:
-2.7425
EPS:
-5.67
ネットキャッシュフロー:
$-594.49M
1週間 パフォーマンス:
-2.57%
1か月 パフォーマンス:
+40.47%
6か月 パフォーマンス:
+39.96%
1年 パフォーマンス:
+3.46%
1日の値動き範囲:
$15.33
$16.42
1週間の範囲:
$15.05
$17.28
52週間の値動き範囲:
$7.48
$18.57
Biohaven Ltd Stock (BHVN) Company Profile
Compare BHVN vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
15.55 | 2.34B | 0 | -647.68M | -594.49M | -5.67 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-13 | 開始されました | Canaccord Genuity | Buy |
| 2026-02-06 | 開始されました | Goldman | Buy |
| 2026-01-21 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-12-03 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-11-26 | ダウングレード | UBS | Buy → Neutral |
| 2025-11-06 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2025-11-05 | ダウングレード | BofA Securities | Buy → Neutral |
| 2025-09-17 | 開始されました | Citigroup | Buy |
| 2025-09-03 | 開始されました | Raymond James | Strong Buy |
| 2025-05-19 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | 開始されました | Deutsche Bank | Buy |
| 2024-09-16 | 開始されました | Jefferies | Buy |
| 2024-09-04 | 開始されました | Bernstein | Outperform |
| 2024-07-24 | 開始されました | Morgan Stanley | Overweight |
| 2024-02-16 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-02-06 | 開始されました | UBS | Buy |
| 2023-12-22 | 開始されました | H.C. Wainwright | Buy |
| 2023-12-08 | 開始されました | Robert W. Baird | Outperform |
| 2023-01-24 | 開始されました | SVB Securities | Outperform |
| 2023-01-04 | 開始されました | JP Morgan | Overweight |
| 2022-12-02 | 開始されました | BTIG Research | Buy |
| 2022-10-26 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2022-10-12 | 開始されました | Piper Sandler | Overweight |
| 2022-08-19 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-08-08 | ダウングレード | Wedbush | Outperform → Neutral |
| 2022-05-11 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-19 | 再開されました | Morgan Stanley | Equal-Weight |
| 2021-08-10 | ダウングレード | UBS | Buy → Neutral |
| 2021-08-03 | 繰り返されました | Canaccord Genuity | Buy |
| 2021-03-11 | 開始されました | UBS | Buy |
| 2020-12-15 | 開始されました | H.C. Wainwright | Buy |
| 2020-04-17 | 開始されました | Cowen | Outperform |
| 2020-02-10 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-02-06 | 開始されました | Mizuho | Buy |
| 2019-11-22 | 開始されました | Wedbush | Outperform |
| 2019-06-25 | 繰り返されました | Canaccord Genuity | Buy |
| 2019-05-06 | 開始されました | Goldman | Buy |
| 2019-04-09 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2019-03-04 | 繰り返されました | Needham | Buy |
| 2018-07-03 | 繰り返されました | Needham | Buy |
| 2018-07-02 | 繰り返されました | Needham | Buy |
| 2018-04-05 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2018-02-22 | 繰り返されました | Canaccord Genuity | Buy |
| 2017-12-15 | 開始されました | Canaccord Genuity | Buy |
| 2017-10-03 | 繰り返されました | Needham | Buy |
すべてを表示
Biohaven Ltd (BHVN) 最新ニュース
Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Co - GuruFocus
Enterprise value to revenue forward of Biohaven Ltd. – NYSE:BHVN - TradingView
Biohaven Research Ltd Shs Unsponsored Brazilian Depositary Receipt Repr 0.33333333 Shs - TradingView
Biohaven announces leadership changes - Hartford Business Journal
Biohaven Announces Scientific Leadership Changes - Contract Pharma
Biohaven (BHVN) Advances Key Trials Following Pipeline Progress While Valuation Still Looks Pricey - simplywall.st
Is Biohaven’s (BHVN) R&D Shake-Up Quietly Redefining Its Late-Stage Pipeline Strategy? - Yahoo Finance
Biohaven Announces Scientific Leadership Transitions - GuruFocus
Biohaven Chief Scientific Officer Bruce Car to Transition to Chief Innovation Officer - Moomoo
Biohaven: Bruce Car, Transitioning From Chief Scientific Officer to Chief Innovation Officer Focusing on External Collaborations >BHVN - Moomoo
Biohaven Announces Leadership Changes to Accelerate CNS Drug Discovery and Innovation Through Bexorg Collaboration – Minichart - Minichart
Biohaven announces leadership changes in discovery unit - Investing.com
Biohaven announces leadership changes in discovery unit By Investing.com - Investing.com South Africa
Biohaven (NYSE: BHVN) shifts CSO to innovation role, promotes discovery head - Stock Titan
Press Release: Biohaven Announces Scientific Leadership Transitions - Moomoo
Biohaven (BHVN) Completes Enrollment in RISE3 Trial - Yahoo Finance
Biohaven (BHVN) Is Up 5.6% After Advancing Two Late-Stage Trials in Epilepsy and Graves’ Disease - Sahm
BHVN Stock Builds Momentum Ahead Of Multiple H2 2026 Clinical Data Readouts - Yahoo Finance
Janus Henderson holds 8.58M Biohaven shares (BHVN) — 5.7% stake - Stock Titan
10 Best Performing American Stocks in June 2026 - Insider Monkey
Why Wall Street Is Growing More Cautious on Biohaven (BHVN) - Insider Monkey
Discipline and Rules-Based Execution in BHVN Response - Stock Traders Daily
BHVNBiohaven Ltd Latest SEC Filings - Finviz
Biohaven Shares Drop 9.8% to $14.28 - Intellectia AI
Biohaven (BHVN) Insider Trading Activity 2026 - MarketBeat
Does Advancing Opakalim and BHV-1300 to Pivotal Trials Change The Bull Case For Biohaven (BHVN)? - simplywall.st
J.P. Morgan Maintains Biohaven(BHVN.US) With Buy Rating - Moomoo
Analyst Warns Biohaven's Lead Drug May Struggle To Stand Out - Sahm
Biohaven completes enrollment in opakalim epilepsy trial - Investing.com
Biohaven completes enrollment in opakalim epilepsy trial By Investing.com - Investing.com Nigeria
Biohaven completes enrollment in focal epilepsy drug trial - StreetInsider
Biohaven's epilepsy drug Opakalim finishes pivotal study enrollment - Stock Titan
Biohaven Shares Down as Phase 3 Trial Concerns Trigger Downgrade at BofA - Moomoo
What's Going On With Biohaven Stock Monday?Biohaven (NYSE:BHVN) - Benzinga
Biohaven (BHVN) Shares Decline Nearly 10% Amid Market Fluctuatio - GuruFocus
BHVN Downgraded by B of A Securities -- Price Target Lowered to $11 - GuruFocus
Biohaven begins phase 3 trial of BHV-1300 for Graves’ disease - Investing.com
BofA Securities Downgrades Biohaven to Underperform From Neutral, Trims Price Target to $11 From $12 - marketscreener.com
Biohaven Doses First Patient in Phase 3 Trial of BHV-1300 for Graves' Disease - marketscreener.com
Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session - Benzinga
Update: BofA Securities Downgrades Biohaven to Underperform From Neutral, Trims Price Target to $11 From $12 - Moomoo
BofA Securities Downgrades Biohaven to Underperform From Neutral, $11 Price Target - Moomoo
BofA downgrades Biohaven stock on epilepsy drug concerns By Investing.com - Investing.com Australia
BofA Securities Downgrades Biohaven(BHVN.US) to Sell Rating, Cuts Target Price to $11 - Moomoo
BofA downgrades Biohaven stock on epilepsy drug concerns - Investing.com
Biohaven's BHV-1300 targets the root cause of Graves' disease in Phase 3 - Stock Titan
BHVN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
BHVN STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
BHVN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Biohaven Ltd (BHVN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Deutsche Bank Adjusts Biohaven Price Target to $20 From $15, Maintains Buy Rating - Moomoo
Biohaven Ltd (BHVN) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):